A further study in KRAS-mutant NSCLC and other KRAS-mutant solid tumour cell lines also reported synergistic cell killing when MAPK pathway inhibitors were combined with BH3 mimetics [40]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.